This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Rydapt
  • /
  • A Global Study of the Efficacy and Safety of Midos...
Clinical trial

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Read time: 3 mins
Last updated:7th Jan 2018
Identifier: NCT03512197

Brief Summary:
The purpose of this study is to confirm the preliminary evidence from early clinical trials that midostaurin may provide clinical benefit not only to AML patients with the FLT3-mutations but also in FLT3-MN (SR<0.05) AML (FLT3 mutant to wild type signal ratio below the 0.05 clinical cut-off).

This study will evaluate the efficacy and safety of midostaurin in combination with daunorubicin or idarubicin and cytarabine for induction and intermediate-dose cytarabine for consolidation, and midostaurin single agent post-consolidation therapy in newly diagnosed patients with FLT3-MN (SR<0.05) AML.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 502 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML)
Actual Study Start Date: January 7, 2018
Estimated Primary Completion Date: October 15, 2019
Estimated Study Completion Date: April 29, 2026

Arms:
- Experimental:
Midostaurin + chemotherapy
- Placebo Comparator: Midostaurin Placebo + chemotherapy

Category Value
Date last updated at source 2019-09-27
Study type(s) Interventional
Expected enrolment 502
Study start date 2018-01-07
Estimated primary completion date 2019-10-15

View full details